Welcome to Library
Annual Reports
RMRIMS News Bulletine
 
Publication of Dr. Krishna Pandey
 

113

Rabi Das VN, Siddiqui NA, Pal B, Lal CS, Verma N, Kumar A, Verma RB, Kumar D, Das P and Pandey K. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). PLoS One. 2017 Mar 29;12(3):e0174497. doi: 10.1371/journal.pone.0174497. eCollection 2017.

112

Kumar R, Pandey K, Sahoo GC, Das S, Das V, Topno RK and Das P. Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis. Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:1465-1471. doi: 10.1016/j.msec.2017.02.145. Epub 2017 Mar 4.

111

Dikhit MR, Amit A, Singh AK, Kumar A, Mansuri R, Sinha S, Topno RK, Mishra R, Das VNR, Pandey K, Sahoo GC, Ali V, Bimal S and Das P. Vaccine potential of HLA-A2 epitopes from Leishmania Cysteine Protease Type III (CPC). Parasite Immunol. 2017 Sep;39(9). doi: 10.1111/pim.12451. Epub 2017 Jul 28.

110

Shivam P, Kumari S, Jamal F, Kumar V, Kumar M, Bimal S, Narayan S, Das VNR, Pandey K, Gupta AK, Das P and Singh SK. Leishmania donovani resistant to Ambisome or Miltefosine exacerbates CD58 expression on NK cells and promotes trans-membrane migration in association with CD2. Cytokine. 2017; 96:54-58. doi: 10.1016/j.cyto.2017.02.005. Epub 2017 Mar 16.

109

Pandey K, Pal B, Das VN, Murti K, Lal CS, Verma N, Bimal S, Ali V, Verma RB, Topno RK, Siddiqi NA and Das P. Safety and efficacy of a combination of Paromomycin and Miltefosine for two versus three courses in patients with Post Kala-Azar Dermal Leishmaniasis (PKDL) - an observational pilot Study. Br J Dermatol. 2017; 177(2):557-559. doi: 10.1111/bjd.15119. Epub 2017 Jul 2.

108

Jamal F, Shivam P, Kumari S, Singh MK, Sardar AH, Pushpanjali, Murugesan S, Narayan S, Gupta AK, Pandey K, Das VNR, Ali V, Bimal S, Das P and Singh SK. Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis. PLoS One. 2017 Aug 18;12(8):e0182474. doi: 10.1371/journal.pone.0182474. eCollection 2017.

107

Pal B, Murti K, Siddiqui NA, Das P, Lal CS, Babu R, Rastogi MK and Pandey K. Assessment of quality of life in patients with post kalaazar dermal leishmaniasis. Health Qual Life Outcomes. 2017; 15(1): 148. doi: 10.1186/s12955-017-0720-y.

106

Sinha KK, Peddada N, Jha PK, Mishra A, Pandey K, Das VN, Ashish and Das P. Plasma Gelsolin Level in HIV-1-Infected Patients: An Indicator of Disease Severity. AIDS Res Hum Retroviruses. 2017; 33(3): 254-260. doi: 10.1089/AID.2016.0154. (Epub 2016 Nov 3).

105

Amit A, Dikhit MR, Mahantesh V, Chaudhary R, Singh AK, Singh A, Singh SK, Das VN, Pandey K, Ali V, Narayan S, Sahoo GC, Das P and Bimal S. Immunomodulation mediated through Leishmania donovani protein disulfide isomerase by eliciting CD8+ T-cell in cured visceral leishmaniasis subjects and identification of its possible HLA class-1 restricted T-cell epitopes. J Biomol Struct Dyn. 2017; 35(1): 128-140. doi: 10.1080/07391102.2015.1134349.  (Epub 2016 Apr 12)

104

Paswan RK, Bimal S, Kumari A, Sinha P, Das VN, Pandey K, Kumar S, Verma RB, Das P and Lal CS. Reduced High Density Lipoprotein Concentration Modulates Increased Interleukin-10 and Decreased Interferon-Gamma in Visceral Leishmaniasis Patients. Gen Med (Los Angel) 2016; 4:233. doi:10.4172/2327-5146.1000233.

 

103

Jamal F, Dikhit MR, Singh MK, Shivam P, Kumari S, Pushpanjali, Dubey AK, Kumar P, Narayan S, Gupta AK, Pandey K, Das VN, Bimal S, Das P and Singh SK. Identification of B-Cell Epitope of Leishmania donovani and its application in Diagnosis of visceral leishmaniasis. J Biomol Struct Dyn. 2016 Nov 28:1-39. [Epub ahead of print]

102

Siddiqui NA, Rabidas VN, Sinha SK, Verma RB, Pandey K, Singh VP, Ranjan A, Topno RK, Lal CS, Kumar V, Sahoo GC, Sridhar S, Pandey A and Das P. Snowball Vs. House-to-House Technique for Measuring Annual Incidence of Kala-azar in the Higher Endemic Blocks of Bihar, India: A Comparison. PLoS Negl Trop Dis. 2016; 10(9): e0004970. doi: 10.1371/journal.pntd.0004970.

101

Das VN, Pandey RN, Siddiqui NA, Chapman LA, Kumar V, Pandey K, Matlashewski G and Das P. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. PLoS Negl Trop Dis. 2016; 10(12): e0005196. doi: 10.1371/journal.pntd.0005196.

100

Ejazi SA, Bhattacharya P, Bakhteyar MA, Mumtaz AA, Pandey K, Das VN, Das P, Rahaman M, Goswami RP and Ali N. Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India. PLoS Negl Trop Dis. 2016; 10(10):e0005035. doi: 10.1371/journal.pntd.0005035.

99

Das S, Mandal R, Rabidas VN, Verma N, Pandey K, Ghosh AK, Kesari S, Kumar A, Purkait B, Lal CS and Das P. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study. PLoS Negl Trop Dis. 2016; 10(10): e0005060. doi: 10.1371/journal.pntd.0005060.

98

Das VN, Pandey RN, Kumar V, Pandey K, Siddiqui NA, Verma RB, Matlashewski G and Das P. Repeated training of accredited social health activists (ASHAs) for improved detection of visceral leishmaniasis cases in Bihar, India. Pathog Glob Health. 2016; 110(1): 33-35. doi: 10.1080/20477724.2016.1156902.

97

Bhattacharya P, Ghosh S, Ejazi SA, Rahaman M, Pandey K, Ravi Das VN, Das P, Goswami RP, Saha B and Ali N. Induction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovani. PLoS Negl Trop Dis. 2016; 10(2):e0004422. doi: 10.1371/journal.pntd.0004422.

96

Kumar R, Das VN, Topno RK, Pal B, Imam A, Agrawal K, Singh A, Murti K, Lal CS, Verma N, Das P and Pandey K. Para-kala-azar dermal Leishmaniasis cases in Indian subcontinent - A case series. Pathog Glob Health. 2016; 110(7-8): 326-329. No abstract available.

95

Singh K, Singh KP, Equbal A, Suman SS, Zaidi A, Garg G, Pandey K, Das P and Ali V. Interaction between cysteine synthase and serine O-acetyltransferase proteins and their stage specific expression in Leishmania donovani. Biochimie. 2016; 131: 29-44. doi: 10.1016/j.biochi.2016.09.004. (Epub 2016 Sep 13).

94

Pandey K, Ravidas V, Siddiqui NA, Sinha SK, Verma RB, Singh TP, Dhariwal AC, Das Gupta RK and Das P. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. Am J Trop Med Hyg. 2016; 95(5): 1100-1105.

93.

Lal CS, Verma RB, Verma N, Siddiqui NA, Rabidas VN, Pandey K, Singh D, Kumar S, Paswan RK, Kumari A, Sinha P and Das P. Hypertriglyceridemia: a possible diagnostic marker of disease severity in visceral leishmaniasis. Infection. 2016; 44(1): 39-45. doi: 10.1007/s15010-015-0811-9. (Epub 2015 Jul 10).

92.

Vijayamahantesh, Amit A, Kumar S, Dikhit MR, Jha PK, Singh AK, Sinha KK, Pandey K, Das VN, Das P and Bimal S. Up regulation of A2B adenosine receptor on monocytes are crucially required for immune pathogenicity in Indian patients exposed to Leishmania donovani. Cytokine. 2016; 79: 38-44. doi: 10.1016/j.cyto.2015.12.016. (Epub 2015 Dec 31).

91.

Kumar R, Sahoo GC, Pandey K, Das VN, Topno RK, Ansari MY, Rana S and Das P. Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis. Mater Sci Eng C Mater Biol Appl. 2016; 59: 748-573. doi: 10.1016/j.msec.2015.10.083. (Epub 2015 Oct 29).

90.

Kumar R, Sahoo GC, Pandey K, Das V, Das P. Study the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovani. Drug Deliv. 2015; 22(3): 383-388. doi: 10.3109/10717544.2014.891271. (Epub 2014 Mar 6).

89.

Zaidi A, Singh KP, Anwar S, Suman SS, Equbal A, Singh K, Dikhit MR, Bimal S, Pandey K, Das P and Ali V. Interaction of frataxin, an iron binding protein, with IscU of Fe-S clusters biogenesis pathway and its upregulation in AmpB resistant Leishmania donovani. Biochimie. 2015; 115: 120-135. doi: 10.1016/j.biochi.2015.05.016. (Epub 2015 May 30).

88.

Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD, Lima MA, Mitra G, Kumar D, Pandey K, Van Geertruyden JP, Boelaert M and Burza S. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clin Infect Dis. 2015; 61(8): 1255-1262. doi: 10.1093/cid/civ530. (Epub 2015 Jun 30).

87.

Verma N, Bimal S, Das VNR, Pandey K, Singh D, Lal CS, Singh AS, Sinha PK and Das P. Clinicopathological and Immunological Changes in Indian Post Kala-Azar Dermal Leishmaniasis (PKDL) Cases in relation to Treatment: A Retrospective Study. BioMed Research International 2015; Article ID 745062. http://dx.doi.org/10.1155/2015/745062

 

86.

Kumari S, Jamal F, Shivam P, Thakur A, Kumar M, Bimal S, Das VN, Pandey K, Narayan S, Gupta AK, Das P and Singh SK. Leishmania donovani skews the CD56(+) Natural Killer T cell response during human visceral leishmaniasis. Cytokine. 2015; 73(1): 53-60. doi: 10.1016/j.cyto.2015.01.011. (Epub 2015 Feb 16).

85.

Yadav A, Amit A, Chaudhary R, Chandel AS, Mahantesh V, Suman SS, Singh SK, Dikhit MR, Ali V, Rabidas V, Pandey K, Kumar A, Das P and Bimal S. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis. Int J Parasitol. 2015; 45(1): 33-42. doi: 10.1016/j.ijpara.2014.08.013. (Epub 2014 Oct 15).

84.

Das P, Amit A, Singh SK, Chaudhary R, Dikhit MR, Yadav A, Pandey K, Das VN, Sundram S, Das P and Bimal S. Leishmania donovani phosphoproteins pp41 and pp29 re-establishes host protective immune response in visceral leishmaniasis. Parasitol Int. 2015; 64(1): 18-25. doi: 10.1016/j.parint.2014.08.004. (Epub 2014 Sep 16).

83.

Shweta SB, Gupta AK, Murti K and Pandey K. Co-infection of visceral leishmaniasis and pulmonary tuberculosis: a case study. Asian Pac J Trop Dis., 2014; 4(1): 57-60.

 

82.

Sethi MK, Khan MA, Murti K, Singh D, Das P and Pandey K. Coinfection Neurocysticercosis and Intracranial Tuberculoma : a rare case. International Journal of Pharmaceutical Science and Health Care, 2014; 4(3): 148-154.

 

81.

Pandey K, Singh D, Bimal S, Murti K and Das P. Association of testosterone and cholesterol level in modulation of immunity and severity of disease in visceral leishmaniasis patients – a preliminary study. American Journal of Immunology, 2014; 10(1): 46-55.

 

80.

Pandey K, Singh D, Bimal S, Rabidas V, Murti K, Lal CS and Das P. Newer drugs for Visceral Leishmaniasis: a review. American Journal of Infectious Diseases, 2014; 10 (2): 68-70.

 

79.

Khan MA, Pandey RK, Nadeem T, Sethi MK, Sharma S, Murti K, Gupta A and Pandey K. Complicated case of Rheumatic Heart disease; unexplored for years. On Line Journal of Biological Sciences, 2014; 14(1): 44-48.

 

78.

Khan MA, Pandey K and Murti K. Pharmacovigilance in India: A Need Indeed. Journal of Pharmacovigilance. 2014, 2: 2.

 

77.

Sethi MK, Singh D, Murti K, Chaudhaery SS, Pandey K and Das P. DPP-4 inhibitors: A novel approach for management of type-2 diabetes mellitus. World J Pharm Sci. 2014; 2(10): 1395-1400.

 

76.

Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Kumar S, Mitra G, Kumar R, Verma N and Das P. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis. 2014; 8(8): e3053. doi: 10.1371/journal.pntd.0003053.

75.

Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S and Das P. Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study. PLoS Negl Trop Dis. 2014; 8(9): e3169. doi: 10.1371/journal.pntd.0003169.

74.

Khan MA, Murti K, Grover V, Lal K, Singh D, Das P and Pandey K. Atorvastatin Vs rosuvastatin; Fenofibrate as an add on: An exploratory study.   Int J Pharm Pharm Sci, 2014; 6(8): 493-498.

 

73.

Sahoo GC, Ansari MY, Rana SP, Dikhit MR, Topno RK, Pandey K and Das P. Molecular Modeling and Ligand-Protein Interaction of N-Protein of Chandipura Virus. Letters in Drug Design & Discovery. 2014; 11(2): 211-221.

 

72.

Negi H, Sarkar M, Raval AD, Pandey K and Das P. Presence of depression & its risk factors in patients with chronic obstructive pulmonary disease. Indian J Med Res. 2014; 139(3): 402-408.

71.

Das VNR, Singh D, Murti K, Das S, Das P and Pandey K. Post Kala-azar Dermal Leishmaniasis with ulceration on foot: An atypical case presentation successfully treated with miltefosine. American Journal of Infectious Diseases, 2014; 10(2): 50-55.

 

70.

Pandey K, Singh D and Das P. Lipodystrophy in an Immuno-compromised Indian Patient with Pulmonary Tuberculosis and Brain Tuberculoma. Indian Journal of Allied Research. 2014; 4 (6): 390-391.

 

69.

Das VN, Pandey RN, Pandey K, Singh V, Kumar V, Matlashewski G and Das P. Impact of ASHA Training on Active Case Detection of Visceral Leishmaniasis in Bihar, India. PLoS Negl Trop Dis. 2014; 8 (5): e2774.

68.

Amit A, Chaudhary R, Yadav A, Suman SS, Narayan S, Das VN, Pandey K, Singh SK, Singh BK, Ali V, Das P and Bimal S. Evaluation of Leishmania donovani disulfide isomerase as a potential target of cellular immunity against visceral leishmaniasis. Cell Immunol. 2014; 289(1-2): 76-85. doi: 10.1016/j.cellimm.2014.03.011.

67.

Negi H, Sarkar M, Raval AD, Pandey K and Das P. Health-related quality of life in patients with chronic obstructive pulmonary disease in North India. J Postgrad Med. 2014; 60(1): 7-11. doi: 10.4103/0022-3859.128797.

66.

Das S, Rani M, Rabidas V, Pandey K, Sahoo GC and Das P. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin–miltefosine combination therapy in visceral leishmaniasis. British Journal of Pharmacology. 2014; 171: 1260–1274.

 

65.

Chaudhary R, Amit A, Yadav A, Singh A, Kumar V, Singh SK, Narayan S, Rabidas V, Pandey K, Kumar A, Das P and Bimal S. Immunomodulation in Human Dendritic Cells Leads to Induction of Interferon-Gamma Production by Leishmania donovani Derived KMP-11 Antigen via Activation of NF-κB in Indian Kala-Azar Patients. Biomed Res Int. 2014; 2014: 947606. doi: 10.1155/2014/947606.

64.

Kumar V, Bimal S, Singh SK, Chaudhary R, Das S, Lal C, Pandey K, Das VR and Das P. Leishmania donovani: Dynamics of L. donovani evasion of innate immune cell attack due to malnutrition in visceral leishmaniasis. Nutrition. 2014; 30(4): 449-458.

63.

Pandey K, Singh D, Das VR, Bimal S, Singh BK and Das P. Progressive Multifocal Leukoencephalopathy Associated with Pulmonary Tuberculosis in an Immuno-Compromised Indian Patient. J AIDS Clin Res. 2013; 4: 9. http://dx.doi.org/10.4172/2155-6113.1000241.

 

62.

Verma N, Singh D, Pandey K, Das VN, Lal CS, Verma RB, Sinha PK and Das P. Comparative Evaluation of PCR and Imprint Smear Microscopy of Skin Biopsy in Diagnosis of Macular, Papular and Mixed Papulo-nodular Lesions of PKDL. J Clin Microbiol. 2013; 51(12): 4217-4219. doi: 10.1128/JCM.01482-13. (Epub 2013 Sep 25).

61.

Shivam P, Jamal F, Kumari S, Bimal S, Narayan S, Das VN, Pandey K, Gupta AK, Singh D, Verma N, Das P and Singh SK. Leishmania donovani: Influence of anti-leishmanial therapy on expression of lymphocyte function-associated antigen-3 and its relevance to pathogenisis in visceral leishmaniasis. Hum Immunol. 2013; 74(12): 1575-1578. doi: 10.1016/j.humimm.2013.08.007. (Epub 2013 Aug 20).

60.

Pandey K, Singh D, Lal C S, Das V, Das P. Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment. J Postgrad Med. 2013; 59(4): 306-308. doi: 10.4103/0022-3859.123161.

59.

Pandey K and Singh D. Stevens Johnson syndrome in a patient with HIV & visceral leishmaniasis. Indian J Med Res. 2013; 138: 368-369.

58.

Khan MA, Kumar RV, Pandey K, Murti K and Gupta AK. Epidemiological survey of visceral leishmaniasis: an evidence based report. Am. J. Infect. Dis. 2013; 9: 59-62. doi:10.3844/ajidsp.2013.59.62.

57.

Das S, Pandey K, Rabidas VN, Mandal A and Das P. Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients. J Antimicrob Chemother. 2013; 68(9): 2059-2065. doi: 10.1093/jac/dkt162. (Epub 2013 May 31).

56.

Matlashewski G, Das VN, Pandey K, Singh D, Das S, Ghosh AK, Pandey RN and Das P. Diagnosis of visceral leishmaniasis in Bihar India: comparison of the rK39 rapid diagnostic test on whole blood versus serum. PLoS Negl Trop Dis. 2013; 23: 7(5): e2233.

55.

Verma N, Lal CS, Rabidas V, Pandey K, Singh D, Kumar S, Verma RB and Das P. Microalbuminuria and glomerular filtration rate in paediatric visceral leishmaniasis. Biomed Res Int. 2013; 2013: 498918. doi: 10.1155/2013/498918. (Epub 2013 Jun 23).

54.

Das V, Pandey K, Singh D, Forwood C, Lal CS and Das P. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India. J Postgrad Med. 2013; 59(3): 226-228. doi: 10.4103/0022-3859.118046.

53.

Lal CS, Kumar S, Ranjan A, Rabidas VN, Verma N, Pandey K, Verma RB, Das S, Singh D and Das P. Comparative analysis of serum zinc, copper, magnesium, calcium and iron level in acute and chronic patients of visceral leishmaniasis. J Trace Elem Med Biol. 2013; 27(2): 98-102. doi: 10.1016/j.jtemb.2012.09.007. (Epub 2012 Nov 28).

52.

Singh D, Pandey K, Das VN, Das S, Verma N, Ranjan A, Lal CS, Topno KR, Singh SK, Verma RB, Kumar A, Sardar AH, Purkait B and Das P. Evaluation of rK-39 Strip Test Using Urine for Diagnosis of Visceral Leishmaniasis in an Endemic Region of India.  Am Am J Trop Med Hyg. 2013; 88(2): 222-226. doi: 10.4269/ajtmh.2012.12-0489. (Epub 2012 Nov 13).

51.

Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J and Arana B. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health. 2013; 18(1): 96-100. doi: 10.1111/tmi.12015. ( Epub 2012 Nov 8).

50.

Das S, Pandey K, Kumar A, Sardar AH, Purkait B, Kumar M, Kumar S, Ravidas VN, Roy S, Singh D and Das P. TGF-β(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol. 2012; 90(6): 640-654. doi: 10.1038/icb.2011.80. ( Epub 2011 Oct 4).

49.

Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, Singh D and Das P. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012; 56(2): 1031-1041. doi: 10.1128/AAC.00030-11. (Epub 2011 Nov 28).

48.

Das S, Rani M, Pandey K, Sahoo GC, Rabidas VN, Singh D and Das P. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro. J Antimicrob Chemother. 2012; 67(10): 2373-2378. (Epub 2012 Jul 3).

47.

Bimal S, Sinha S, Singh SK, Narayan S, Kumar V, Verma N, Ranjan A, Sinha PK, Das VN, Pandey K, Kar SK and Das P. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection. Exp Parasitol. 2012; 131(3): 274-282. (Epub 2012 May 10).

46.

Das VNR, Ranjan A, Pandey K, Singh D, Verma N, Das S, Lal CS, Sinha NK, Verma RB, Siddiqui NA, and Das P. Short Report: Clinico-Epidemiologic Profile of a Cohort of Post–Kala-Azar Dermal Leishmaniasis Patients in Bihar, India. Am. J. Trop. Med. Hyg., 2012; 86(6): 959–961.

45.

Pandey K, Das VN, Singh D, Das S, Lal CS, Verma N, Bimal S, Topno RK, Siddiqui NA, Verma RB, Sinha PK and Das P. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. J Clin Microbiol. 2012; 50(4): 1478-1479. (Epub 2012 Jan 25).

44.

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P and Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet, 2011; 377(9764): 477-486. (Epub 2011 Jan 20).

 

43.

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H and Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg, 2011; 105(2): 115-117 (Epub 2010 Dec 3).

42.

Ghosh J, Lal CS, Pandey K, Das VN, Das P, Roychoudhury K and Roy S. Human visceral leishmaniasis: decrease in serum cholesterol as a function of splenic parasite load. Ann Trop Med Parasitol., 2011; 105(3): 267-271.

41.

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M and Palma PP. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in bihar, India Clin Infect Dis., 2011; 53(7): e91-e98. (doi:10.1093/cid/cir521).

 

40.

Kumar N, Sinha PK, Pandey K, Verma N, Lal CS, Ranjan A, Verma RB and Das P. A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy. International Journal of Clinical Pharmacy, 2011; Jul 22. [Epub ahead of print].

39.

Das S, Pandey K, Kumar A, Sardar AH, Purkait B, Kumar M, Kumar S, Ravidas VN, Roy S, Singh D and Das P. TGF-β(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol, 2011; Oct 4. doi: 10.1038/icb. 2011.80. [Epub ahead of print]

38.

Das VN, Siddiqui NA, Verma RB, Topno RK, Singh D, Das S, Ranjan A, Pandey K, Kumar N and Das P. Asymptomatic infection of visceral leishmaniasis in hyperendemic areas of Vaishali district, Bihar, India: a challenge to kala-azar elimination programmes. Trans R Soc Trop Med Hyg, 2011; 105(11): 661-666. (Epub 2011 Sep 25).

37.

Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, Singh D and Das P. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrob Agents Chemother. 2011 Nov 28. [Epub ahead of print]

36.

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P and Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet, 2011; 377(9764): 477-486. (Epub 2011 Jan 20)

 

35.

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H and Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg, 2011;105(2): 115-7 (Epub 2010 Dec 3).

34.

Topno RK, Das VN, Ranjan A, Pandey K, Singh D, Kumar N, Siddiqui NA, Singh VP, Kesari S, Kumar N, Bimal S, Kumar AJ, Meena C, Kumar R and Das P. Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India. Am J Trop Med Hyg. 2010; 83(3): 502-506

33.

Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F and Pandey K. Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India. Am J Trop Med Hyg. 2010; 83(2): 357-364.

32.

Das VNR, Pandey K, Verma N, Bimal S, Lal CS, Singh D and Das P. Post-kala-azar dermal leishmaniasis(PKDL), HIV and pulmonary tuberculosis . National Medical Journal of India. 2010; 23(2): 88-89.

31.

Siddiqui NA, Kumar N, Ranjan A, Pandey K, Das VNR, Verma RB and Das P. Awareness about Kala-azar disease and related preventive attitudes and practices in a highly endemic rural area of India.  Southeast Asian journal of tropical medicine and public health. 2010; 41(1): 1-12.

30.

Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, Kumar N, Pandey K and Das P. Estimation of under reporting of Visceral Leishmaniasis cases in Bihar, India. . American Journal of Tropical Medicine Hygiene .2010; 82(1): 9-11.


29.

Lal CS, Verma N, Rabidas VN, Ranjan A, Pandey K, Verma RB, Singh D, Kumar S and Das P. Total serum cholesterol determination can provide understanding of parasite burden in patients with visceral leishmaniasis infection. Clin Chim Acta. 2010; 411(23-24): 2112-2113. (Epub 2010 Sep 8).

28.

Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB and Das P. Development of Post Kala-Azar Dermal Leishmaniasis (PKDL) in Miltefosinetreated visceral leishmaniasis. American Journal of Tropical Medicine and Hygiene. 2009; 80(3): 336-338.


27.

Banerjee S, Ghosh J, Sen S, Guha R, Dhar R, Ghosh M, Datta S, Raychaudhury B, Naskar K, Haldar AK, Lal CS, Pandey K, Das VN, Das P and Roy S. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infection and immunity, 2009, 77(6): 2330-2342.


26.

Das VN, Siddiqui NA, Pandey K, Singh VP, Topno RK, Singh D, Verma RB, Ranjan A, Sinha PK and Das P. A controlled, randomized nonblinded clinical trial to assess the effi cacy of  mphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Therapeutics and Clinical Risk Management, 2009; 5: 117–124.


25.

Khan AM, Pandey K, Kumar V, Dutta P, Das P and Mahanta J. Sample survey for indigenous cases of kala-azar in Assam by rk39 dipstick test. Indian J Med Res. 2009; 129(3): 327-328.


24.

Singh D, Pandey K, Das VN, Das S, Kumar S, Topno RK and Das P. Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples. J Clin Microbiol. 2009; 47(8): 2684-2685.


23.

Pandey K, Sinha PK, Das VN, Bimal S, Singh SK and Das P. Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario. Clinical Medicine: Pathology, 2009; 2: 1–4.

 

22.

Pandey K, Sinha PK, Das VN, Nawin Kumar, Bimal S, Verma RB, Verma N, Lal CS, Topno RK, Siddiqui NA, Singh D and Das P. Tuberous sclerosis with visceral leishmaniasis: a case report. Journal of Medical Case Reports, 2009; 3: 9027.


21.

Bimal S, Singh SK, Sinha S, Pandey K, Sinha PK, Ranjan A, Bhattacharya SK and Das P. Leishmania donovani: Role of CD2 on CD4+ T – cell function in Visceral leishmaniasis. Exp. Parasitol., 2008; 118(2): 238-246.

20.

Sinha PK, Bimal S, Pandey K, Singh SK, Ranjan A, Kumar N, Lal CS, Barman SB, Verma RB, Jeyakumar A, Das P, Bhattacharya M, Sur D and Bhattacharya SK. A community-based, comparative evaluation of direct agglutination and rK39 strip tests in the early detection of subclinical Leishmania donovani infection. Ann. Trop. Med. & Parasitol, (2008); 102(2): 119-125.

19.

Kumar N, Pandey K, Das VN, Sinha PK, Topno RK, Lal CS, Bimal S, Verma N and Das P. HIV infection, visceral leishmaniasis and Guillain –Barre syndrome in same patient: a case report. Ann. Trop. Med. & Parasitol, 2008; 102(2): 185-188.

18.

Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Pradeep Das, Choudhuri SK and Roy S. Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection. Antimicrob Agents Chemother, 2008; 52(3): 1080-1093.


17.

Topno RK, Pandey K, Das VN, Kumar N, Bimal S, Verma RB, Siddiqui NA, Singh D, Kumar R, Kumar P, Ranjan A, Das P and Sinha PK. Visceral Leishmaniasis in pregnancy – role of Amphotericin B. Ann. Trop. Med. & Parasitol, 2008; 102(3): 267-270.

16.

Pandey K, Sinha PK, Rabidas V, Kumar N, Bimal S, Verma N, Lal C and Das P. HIV, visceral leishmaniasis and Parkinsonism combined with diabetes mellitus and hyperuricaemia: A case report. Cases Journal, 2008; 1: 183.


15.

Kumar N, Pandey K, Das VN, Sinha PK, Topno RK, Verma N, Lal CS, Das P and Bhattacharya SK. Miltefosine in the Treatment of a case of Visceral Leishmaniasis with Renal Dysfunction. Ann Trop Med Parasitol., 2007;101(7): 649-651.

14.

Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H and Ganguly NK. Phase IV Trial of Miltefosine in the Treatment of Indian Visceral Leishmaniasis.J Infect Dis. 2007; 196(4): 591-598.


13.

Lal CS, Kumar A, Kumar S, Pandey K, Kumar N, Bimal S, Sinha PK and Das P. Hypocholesterolemia and increased triglycerides in paediatric visceral leishmaniasis. Clinica Chimica Acta, 2007; 382(1-2): 151-153.


12.

Pandey K, Sinha PK, Das VN, Kumar N, Verma N, Bimal S, Lal CS, Topno RK, Singh D, Verma RB, Bhattacharya SK and Das P. Wilson Disease with Visceral Leishmaniasis: An Extremely Uncommon Presentation. Am J Trop Med Hyg. 2007; 77(3): 560 – 561.

11.

Sinha PK, Bimal S, Singh SK, Pandey K, Gangopadhyay DN, And Bhattacharya SK. Pre and Post Treatment evaluation of Immunological features in Indian Visceral Leishmaniasis patient with HIV Co-Infection. Indian J Med Res., 2006; 123: 197-202.


10.

Sinha PK, Ranjan A, Singh VP, Das VNR, Pandey K, Kumar N, Verma N, Lal CS, Sur D, Manna B and Bhattacharya SK. Visceral Leishmaniasis (Kala-azar)-the Bihar (India) perspective. J Infect. 2006; 53(1): 60-64.

9.

Das VN, Pandey K, Kumar N, Hassan SM, Bimal S, Lal CS, Siddiqui NA and Bhattacharya SK. Visceral leishmaniasis and tuberculosis in patients with HIV co-infection. Southeast Asian J Trop Med Public Health, 2006; 37(1): 18-21.


8.

Pranati, Bimal S, Pandey K, Sinha PK, Gupta AK, Singh SK, Sundaram S and Das P. Leishmania donovani: Immunomodulatory Role of 63KDa Leishmania Antigen in the Promotion of IFN-gamma Response (VL vs HIV-VL Co-infection). Am. J. Immunol., 2006; 2(2): 52-57.

 

7.

Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK and Bhattacharya SK. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis
in Bihar. Natl Med J India, 2005; 18(3): 131-133.


6.

Das VNR, Pandey K, Kumar N, Hassan SM, and Bhattacharya SK. HIV Infection, Pneumonic Patch with Tuberculosis and Hepatitis- A case Report. Journal of communicable Diseases. 2005; 37(2): 155-157.

5.

Pandey K, Sinha PK, Das VN, Kumar N, Hassan SM, Verma N, Lal CS, Bimal S, Das P and Bhattacharya SK. HIV-I infection, visceral leishmaniasis, Koch's chest and tuberculous meningitis in the same patient- a case report. Ann Trop Med Parasitol. 2005; 99(8): 807-811.

4.

Sinha PK, Pandey K and Bhattacharya SK. Diagnosis & Management of Leishmania/ HIV Co-Infection. Indian J Med Res., 2005; 121: 407-414.


3.

Pandey K, Sinha PK, Das VNR, Sur D, Kumar Nawin, and Bhattacharya SK. Neurocysticercosis in a Patient With Visceral Leishmaniasis Co-infected With HIV: A Case Report. Infectious Disease in Clinical Practice. 2005; 13(3): 1-2.

 

2.

Bimal S,  Singh S, Pandey K, Sinha PK, Das PK, Schallig H, Das P and Bhattacharya SK. Comparative evaluation of aqueous and freeze dried antigen for Sero-diagnosis of VL and PKDL cases by DAT. American Journal of Immunology, 2005; 1(2): 74-78.

 

1.

Sinha PK, Rabidas VN, Pandey K, Verma N, Gupta AK, Ranjan A, Das P and Bhattacharya SK. Visceral Leishmaniasis and HIV Coinfection in Bihar, India. Letter to Editor, J Acquire Immune Defic Syndr. 2003; 32(1): 115-116.